Analysis of the results of sleeve gastrectomy for morbid obesity and the role of ghrelin

Surgery Today

Volumn 38, Issue 6, 2008, Pages 481-483

  Frezza, Eldo E ^a   Chiriva Internati, Maurizio ^a   Wachtel, Mitchell S ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Ghrelin; Morbid obesity; Percent excess weight loss; Sleeve gastrectomy

Indexed keywords

GHRELIN;

BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BODY MASS; FOLLOW UP; GASTRECTOMY; HUMAN; MORBID OBESITY; PROTEIN BLOOD LEVEL; REVIEW; SLEEVE GASTRECTOMY; STOMACH FUNDUS; SURGICAL RISK; SURGICAL TECHNIQUE; WEIGHT REDUCTION;

BARIATRIC SURGERY; GHRELIN; HUMANS; LAPAROSCOPY; OBESITY, MORBID;

EID: 44449156395     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-007-3648-8     Document Type: Review

References (26)

1. Marceau P, Biron S, Bourque RA, Potvin M, Hould FS, Simard S. Biliopancreatic diversion with a new type of gastrectomy. Obes Surg 1993;3(1):29-35.
2. Gagner M, Steffen R, Biertho L, Horber F. Laparoscopic adjustable gastric banding with duodenal switch for morbid obesity: technique and preliminary results. Obes Surg 2003;13(3):444-449.
3. Frezza EE. Laparoscopic vertical sleeve gastrectomy for morbid obesity. The future procedure of choice? Surg Today 2007;37:275-281.
4. Roa PE, Kaidar-Person O, Pinto D, Cho M, Szomstein S, Rosenthal RJ, et al. Laparoscopic sleeve gastrectomy as treatment for morbid obesity: technique and short-term outcome. Obes Surg 2006;16:1323-1326.
5. Regan JP, Inabnet WB, Gagner M, Pomp A. Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. Obes Surg 2003;13:861-864.
6. Milone L, Strong V, Gagner M. Laparoscopic sleeve gastrectomy is superior to endoscopic intragastric balloon as first stage procedure for super-obese patients. Obes Surg 2005;15:612-617.
7. Mognol P, Chosidow D, Marmuse JP. Laparoscopic sleeve gastrectomy as an initial bariatric operation for high-risk patients: initial results in 10 patients. Obes Surg 2005;15:1030-1033.
8. Han MS, Kim WW, Oh JH. Results of laparoscopic sleeve gastrectomy at 1 year in morbidly obese Korean patients. Obes Surg 2005;15:1469-1475.
9. Bernante P, Foletto M, Busetto L, Pomerri F, Pesenti FF, Pelizzo MR, et al. Feasibility of laparoscopic sleeve gastrectomy as a revision procedure for prior laparoscopic gastric banding. Obes Surg 2006;16:1327-1330.
10. Langer FB, Bohdjalian A, Felberbauer FX, Fleischmann E, Reza Hoda MA, Ludvik B, et al. Does gastric dilatation limit the success of sleeve gastrectomy as a sole operation for morbid obesity? Obes Surg 2006;16:166-171.
11. Almogy G, Crookes, PF, Anthone GJ. Longitudinal gastrectomy as a treatment for the high-risk super-obese patient. Obes Surg 2004;14:492-497.
12. Deitel M, Greenstein RJ. Recommendations for reporting weight loss. Obes Surg 2003;13(2):159-160.
13. Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX, Zacherl J, Wenzl E, et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg 2005;15(7):1024-1029.
14. Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX, Zacherl J, Wenzl E, et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg 2005;15:1024-1029.
15. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, et al. Stomach is a major source of circulation ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001;86:4753-4758.
16. Lin E, Gletsu N, Fugate K, McClusky D, Gu LH, Zhu JL, et al. The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. Arch Surg 2004;139:780-784.
17. Broglio F, Koetsveld PV, Benso A, Gottero C, Prodam F, Papotti M, et al. Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J Clin Endocrinol Metab 2002;87:4829-4832.
18. Norrelund H, Hansen TK, Orskov H, Hosoda H, Kojima M, Kangawa K, et al. Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. Clin Endocrinol (Oxf) 2002;57:539-546.
19. Frezza EE, Wachtel MS, Chiriva-Internati. The multiple faces of glucagon-like peptide 1-obesity, appetite, and stress: what is next? A Review. DDS 2007;52(3):643-649.
20. Frezza, EE. Are we closer in finding the treatment for type II diabetes mellitus in morbid obesity - are the incretins the key to success? Obes Surg 2004;14(7):999-1005.
21. Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 2002;440:269-279.
22. Christou NV, Look D, McLean AP. Pre and post-prandial plasma ghrelin levels do not correlate with satiety or failure to achieve a successful outcome after Roux-en-Y gastric bypass. Obes Surg 2005;15(7):1017-1023.
23. Ikezaki A, Hosoda H, Ito K, Iwama S, Miura N, Matsuoka H, et al. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 2002;51(12):3408-3411.
24. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 2003;52:1098-1103.
25. Lin E, Gletsu N, Fugate K, McClusky D, Gu LH, Zhu JL, et al. Insulin-associated downregulation of ghrelin expression in the morbidly obese and type-2 diabetes (DM). J Am Coll Surg 2003;197(suppl 3):S9.
26. Lee CM, Feng JJ, Cirangle PT, Jossart GH. Laparoscopic vertical sleeve gastrectomy for morbid obesity in 216 patients: report of two-year results. Presented at SAGES, Dallas, Texas, April 28, 2006.